Levoketoconazole
Recorlev (levoketoconazole) is a small molecule pharmaceutical. Levoketoconazole was first approved as Recorlev on 2021-12-30. It is used to treat acanthamoeba keratitis, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, and cutaneous candidiasis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Recorlev
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levoketoconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RECORLEV | Strongbridge Biopharma | N-214133 RX | 2021-12-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nizoral | New Drug Application | 2024-09-20 |
| nizoral eczema relief cream | C200263 | 2024-01-05 |
| nizoral psoriasis | C200263 | 2024-09-18 |
| nizoral psoriasis relief | C200263 | 2024-01-05 |
| nizoral scalp itch relief | C200263 | 2024-01-05 |
| recorlev | New Drug Application | 2023-06-16 |
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LEVOKETOCONAZOLE, RECORLEV, STRONGBRIDGE | |||
| 2028-12-30 | ODE-385 | ||
HCPCS
No data
Clinical
Clinical Trials
211 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 21 | 3 | — | 2 | — | 26 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | 2 | 1 | 2 | 7 |
| Seborrheic dermatitis | D012628 | HP_0001051 | L21 | — | 2 | 1 | 1 | 2 | 6 |
| Tinea versicolor | D014010 | EFO_0007439 | B36.0 | 1 | — | — | 3 | — | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 1 | 1 | — | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | 1 | 1 | 3 |
| Recurrence | D012008 | — | — | 2 | — | — | 1 | — | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | 1 | — | 3 |
| Thromboembolism | D013923 | HP_0001907 | — | — | 1 | — | 1 | — | 2 |
| Pityriasis | D010915 | — | — | — | — | — | 2 | — | 2 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 3 | 20 | 6 | — | 4 | 31 |
| Tinea | D014005 | EFO_0007510 | B35.9 | 1 | 1 | 6 | — | 1 | 9 |
| Tinea pedis | D014008 | EFO_0007512 | B35.3 | — | 1 | 5 | — | — | 6 |
| Candidiasis | D002177 | — | B37 | — | — | 4 | — | 1 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | 3 | 1 | — | — | 5 |
| Syndrome | D013577 | — | — | — | — | 4 | — | 1 | 5 |
| Infections | D007239 | EFO_0000544 | — | 2 | — | 1 | — | 1 | 4 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | 3 | — | 1 | 4 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | 1 | — | 2 | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | 1 | — | — | 3 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
| Hypogonadism | D007006 | HP_0000044 | E23.0 | 1 | 1 | — | — | 1 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 2 | 2 | — | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | 1 | 2 | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 2 | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Granulosa cell tumor | D006106 | — | — | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 51 | — | — | — | 1 | 52 |
| Pharmacokinetics | D010599 | — | — | 6 | — | — | — | — | 6 |
| Lymphoma | D008223 | — | C85.9 | 5 | — | — | — | — | 5 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | — | — | — | — | 3 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | 1 | 3 |
| Hepatitis c | D006526 | — | B19.2 | 2 | — | — | — | — | 2 |
| Sleep deprivation | D012892 | — | F51.12 | 2 | — | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
Show 33 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| Gonadal disorders | D006058 | — | — | — | — | — | — | 1 | 1 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Tinea capitis | D014006 | — | B35.0 | — | — | — | — | 1 | 1 |
| Cryptorchidism | D003456 | EFO_0004562 | Q53.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levoketoconazole |
| INN | levoketoconazole |
| Description | (2S,4R)-ketoconazole is a cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2S,4R)-configuration. It is an enantiomer of a (2R,4S)-ketoconazole. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 142128-57-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL295698 |
| ChEBI ID | 47518 |
| PubChem CID | 47576 |
| DrugBank | DB05667 |
| UNII ID | 2DJ8R0NT7K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Recorlev – Xeris Biopharma Holdings
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 413 documents
View more details
Safety
Black-box Warning
Black-box warning for: Recorlev
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,364 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use